Literature DB >> 30191055

'Hug sign': a new radiological sign of intraprocedural success after combined treatment for hepatocellular carcinoma.

Roberto Iezzi1,1, Maurizio Pompili2,2, Eleonora Brigida Annicchiarico2,2, Matteo Garcovich2,2, Massimo Siciliano2,2, Antonio Gasbarrini2,2, Riccardo Manfredi1,1.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. A careful multidisciplinary assessment of tumor characteristics, liver function and physical status is required for proper therapeutic management. In recent years, several studies have supported the feasibility and benefit of combined therapy in the treatment of single large HCC, defined as those exceeding 3 cm in size. We present a case of combined treatment using radiofrequency ablation followed by trans-arterial chemoembolization with radiopaque embolic beads. The aim of this technical report was to describe the radiologic findings during combined radiofrequency ablation and radiopaque bead embolization, pointing out the differences and the potential advantages of using radiopaque beads compared with non-radiopaque beads. Furthermore, it is also the first report on using radiopaque beads in combined treatment for HCC.

Entities:  

Keywords:  CB-CT; HCC; ablation; chemoembolization; combined treatment; follow-up; mRECIST criteria; radiopaque beads; safety margin; unresectable

Year:  2017        PMID: 30191055      PMCID: PMC6095315          DOI: 10.2217/hep-2017-0017

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN: 2045-0923


  4 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

Review 2.  Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis.

Authors:  Yulan Wang; Tianxing Deng; Li Zeng; Weiqing Chen
Journal:  Hepatol Res       Date:  2015-09-02       Impact factor: 4.288

Review 3.  Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art.

Authors:  Roberto Iezzi; Maurizio Pompili; Alessandro Posa; Giuseppe Coppola; Antonio Gasbarrini; Lorenzo Bonomo
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

4.  Characterization of a novel intrinsically radiopaque Drug-eluting Bead for image-guided therapy: DC Bead LUMI™.

Authors:  Koorosh Ashrafi; Yiqing Tang; Hugh Britton; Orianne Domenge; Delphine Blino; Andrew J Bushby; Kseniya Shuturminska; Mark den Hartog; Alessandro Radaelli; Ayele H Negussie; Andrew S Mikhail; David L Woods; Venkatesh Krishnasamy; Elliot B Levy; Bradford J Wood; Sean L Willis; Matthew R Dreher; Andrew L Lewis
Journal:  J Control Release       Date:  2017-02-08       Impact factor: 9.776

  4 in total
  2 in total

Review 1.  Bench-to-clinic development of imageable drug-eluting embolization beads: finding the balance.

Authors:  Andrew L Lewis; Sean L Willis; Matthew R Dreher; Yiqing Tang; Koorosh Ashrafi; Bradford J Wood; Elliot B Levy; Karun V Sharma; Ayele H Negussie; Andrew S Mikhail
Journal:  Future Oncol       Date:  2018-06-26       Impact factor: 3.404

2.  Handling and performance characteristics of a new small caliber radiopaque embolic microsphere.

Authors:  Andrew L Lewis; Marcus Caine; Pedro Garcia; Koorosh Ashrafi; Yiqing Tang; Lorcan Hinchcliffe; Wei Guo; Zainab Bascal; Hugh Kilpatrick; Sean L Willis
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2020-06-23       Impact factor: 3.368

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.